Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors-Reference-Cited by-同舟云学术

Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors

Published:2017-06-01 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Zhu Yanni,Bassoff Nicole,Reinshagen Clemens^ORCID,Bhere Deepak,Nowicki Michal O.,Lawler Sean E.,Roux Jérémie^ORCID,Shah Khalid

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-02483-9.pdf

Reference52 articles.

1. Nicholson, R. I., Gee, J. M. & Harper, M. E. EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4), S9–15, doi: 10.1016/S0959-8049(01)00231-3 (2001).

2. Selvaggi, G. et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 15, 28–32, doi: 10.1093/annonc/mdh011 (2004).

3. Shinojima, N. et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer research 63, 6962–6970 (2003).

4. Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527–1537, doi: 10.1016/S0140-6736(05)67625-8 (2005).

5. Martinelli, E., De Palma, R., Orditura, M., De Vita, F. & Ciardiello, F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clinical and experimental immunology 158, 1–9, doi: 10.1111/j.1365-2249.2009.03992.x (2009).

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic stem cells engineered to release interferon β and scFv-PD1 target glioblastoma and alter the tumor microenvironment;Cytotherapy;2024-05

2. Developing and characterizing a two-layered safety switch for cell therapies;Cancer Biology & Therapy;2023-07-13

3. Fate and Efficacy of Engineered Allogeneic Stem Cells Targeting Cell Death and Proliferation Pathways in Primary and Brain Metastatic Lung Cancer;Stem Cells Translational Medicine;2023-06-13

4. Engineered cell-based therapies in ex vivo ready-made CellDex capsules have therapeutic efficacy in solid tumors;Biomedicine & Pharmacotherapy;2023-06

5. Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions;Frontiers in Immunology;2023-05-25